Topical prophylaxis for HIV prevention in women: Becoming a reality

Natasha Nakra, Anna C. Lee, Betsy C. Herold, Marla J. Keller

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Strategies to protect against sexual transmission of HIV include the development of products formulated for topical application, which limit the toxicities associated with systemic oral pre-exposure prophylaxis. Following several clinical trial failures, attention is now focused on antiretroviral (ARV) agents. Highly potent ARV topical formulations provide a female-controlled, targeted, and feasible option for HIV prevention. A recently completed tenofovir gel trial was the first to demonstrate significant protection against HIV acquisition. Topical ARVs have the advantage of delivering high concentration of drug at the site of transmission of HIV, with low systemic absorption. Sustained-release formulations, such as intravaginal rings, will likely improve adherence and can be designed to provide controlled and continuous delivery of ARV combinations. Further studies to test alternative dosing strategies and pharmacokinetic/pharmacodynamic relationships in the genital tract will provide valuable information as the field strives to improve upon the promising tenofovir gel trial results.

Original languageEnglish (US)
Pages (from-to)104-113
Number of pages10
JournalCurrent HIV/AIDS Reports
Volume8
Issue number2
DOIs
StatePublished - Jun 2011
Externally publishedYes

    Fingerprint

Keywords

  • Adherence
  • Antiretroviral drugs
  • Biomarkers
  • Dapivirine
  • Genital tract
  • Herpes simplex virus
  • Human immunodeficiency virus
  • Intravaginal ring
  • Maraviroc
  • Pharmacodynamics
  • Pharmacokinetics
  • Pre-exposure prophylaxis
  • Tenofovir
  • Topical microbicides

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this